Myeloid dendritic cell (mDC)

Myeloid dendritic cell" refers to a heterogeneous population of professional antigen-presenting cells that originate from myeloid progenitors, not a single molecule or receptor[1][2][7]. These cells, also called conventional or classical dendritic cells, play a central role in initiating adaptive immune responses by capturing, processing, and presenting antigens to T cells[1][2][4][3]. Myeloid dendritic cells are essential for both immunity (e.g., pathogen defense, tumor surveillance) and immune tolerance (regulating self-reactivity to prevent autoimmunity)[2][4][7]. They are divided into major subsets (e.g., cDC1, cDC2), identified by surface markers such as CD11c, CD1c, or CD141[5][7]. mDCs are functional, cellular components of the immune system—not canonical therapeutic targets like receptors, enzymes, or ion channels. As such, no drugs directly target "myeloid dendritic cell" as a molecular entity, though mDCs are manipulated indirectly in immunotherapy (e.g., as cellular targets in cancer vaccines or in modulating immune responses)[5][6][1]. Therefore, "myeloid dendritic cell" is not a valid molecular drug target but a cell type crucial to immunity and immune modulation. Key rationale for "is_incorrect: true": "Myeloid dendritic cell" is a cell type, not a molecule, receptor, or canonical target for drugs as conventionally defined—there is no single sequence, structure, or gene product that can be mapped to it. It may be listed as a scientific target in immunology studies or vaccine design but is not a molecular target per se according to conventional drug or target databases[1][2][5][7].

Other names

Conventional dendritic cellcDCClassical dendritic cellcDC1cDC2Antigen-presenting cell (professional, myeloid lineage)